This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Medimmune Limited. Active years: 2019-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2023
Title: Innovations by Shengyan Hong in Cancer Treatment
Introduction
Shengyan Hong is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic antibodies. With a total of 3 patents, his work focuses on targeting specific proteins that play a role in tumor growth.
Latest Patents
Among his latest patents, Shengyan Hong has developed Anti-B7-H1 antibodies for treating tumors. These patents detail methods of treating B7-H1-expressing tumors by administering an effective amount of MEDI4736 or an antigen-binding fragment thereof. This innovative approach aims to enhance the efficacy of cancer treatments by specifically targeting tumor cells.
Career Highlights
Shengyan Hong is currently associated with MedImmune Limited, where he continues to advance his research in oncology. His work has been instrumental in developing new therapeutic strategies that could potentially improve patient outcomes in cancer treatment.
Collaborations
Shengyan collaborates with esteemed colleagues such as Rajesh Narwal and David Fairman. Their combined expertise contributes to the innovative environment at MedImmune Limited, fostering advancements in cancer therapies.
Conclusion
In summary, Shengyan Hong's contributions to cancer treatment through his patented innovations highlight the importance of targeted therapies in modern medicine. His work continues to pave the way for new treatment options that could significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile